STAAR Surgical (STAA) awards 39,809 RSUs to Interim Co-CEO Andrews

Rhea-AI Filing Summary

ANDREWS DEBORAH J reported acquisition or exercise transactions in this Form 4 filing.

STAAR Surgical granted Interim Co-CEO and CFO Deborah J. Andrews 39,809 restricted stock units (RSUs) on March 13, 2026 as an annual equity award. Each RSU represents one share of common stock and vests in three equal installments through March 13, 2029.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ANDREWS DEBORAH J

(Last) (First) (Middle)

25510 COMMERCENTRE DRIVE

(Street)

LAKE FOREST CA 92630

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
STAAR SURGICAL CO [ STAA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim Co-CEO and CFO

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(1)	03/13/2026		A		39,809		(2)	(2)	Common Stock	39,809	$0	39,809	D

Explanation of Responses:

1. Each restricted stock unit (RSU) represents the right to receive one share of the Corporation's common stock upon vesting.

2. Reflects RSUs granted to the Reporting Person on March 13, 2026 in connection with annual equity award. These RSUs vest as to 1/3 (13,269 shares) on March 13, 2027, 1/3 (13,270 shares) on March 13, 2028, and 1/3 (13,270 shares) on March 13, 2029.

	/s/ Deborah Andrews	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity award did STAAR Surgical (STAA) grant to Deborah J. Andrews?

Deborah J. Andrews received 39,809 restricted stock units (RSUs). The award was granted as part of her annual equity compensation, with each RSU representing the right to receive one share of STAAR Surgical common stock upon vesting.

When did Deborah J. Andrews receive her STAAR Surgical RSU grant?

The RSU grant was made on March 13, 2026. On that date, STAAR Surgical granted 39,809 restricted stock units to Interim Co-CEO and CFO Deborah J. Andrews as an annual equity award tied to the company’s common stock.

How do the 39,809 RSUs granted to Deborah J. Andrews vest at STAAR Surgical (STAA)?

The RSUs vest in three annual installments. Vesting occurs as to 13,269 shares on March 13, 2027, 13,270 shares on March 13, 2028, and 13,270 shares on March 13, 2029, assuming continued service through each vesting date.

What does each restricted stock unit represent in the STAAR Surgical grant to Deborah J. Andrews?

Each RSU represents one share of common stock. Upon vesting, each restricted stock unit converts into a single share of STAAR Surgical’s common stock, delivering equity-based compensation directly linked to the company’s share value.

What role does Deborah J. Andrews hold at STAAR Surgical (STAA) in connection with this RSU grant?

Deborah J. Andrews serves as Interim Co-CEO and CFO. Her position as a senior executive is tied to the 39,809 restricted stock units granted as an annual equity award, aligning her compensation with STAAR Surgical’s long-term shareholder interests.